Abstract: Compounds of the formula ##STR1## wherein D is a diazo component radical,K is the radical of a coupling component of the 1,4-phenylene or 1,4-naphthylene series,R.sub.1 is hydrogen; alkyl; or alkenyl; and when K is a coupling component radical of the 1,4-phenylene series, R.sub.1 is also alkenyl monosubstituted by halogen; or alkyl which is substituted by a halogen, hydroxy, alkoxy, acyloxy, phenyl, phenoxy, cyano, alkenyloxy, alkynyloxy or alkoxyalkynyloxy group and is optionally further substituted by a hydroxy group,R.sub.2 is hydrogen, acyl, alkyl or alkyl monosubstituted by halogen, alkoxy, phenyl, phenoxy, benzyloxy, hydroxy or acyloxy and ##STR2## with the proviso that when R.sub.4 is ##STR3## K is a coupling component radical of the 1,4-naphthylene series, R.sub.5 is hydrogen, or ##STR4## each of R.sub.3 and R.sub.3 ' is independently hydrogen or alkyl, or R.sub.3 and R.sub.3 ' together with the carbon atom to which they are bound form a cyclohexane ring, with the proviso that when R.sub.3 and R.sub.

Abstract: Agents for lowering glucose levels in blood having the formula: ##STR1## wherein R.sub.o is bromo, chloro, fluoro, nitro or trifluoromethyl,R is hydrogen, C.sub.1-6 alkyl or C.sub.2-18 alkanoyl, andR.sub.1 is hydrogen or C.sub.1-12 alkyl,and the non-toxic, pharmaceutically acceptable salts thereof.

Abstract: The compounds of formula I ##STR1## wherein R.sub.1 is hydrogen or methyl,R.sub.3 is hydrogen, methyl, hydroxymethyl, carboxyl, alkoxycarbonyl of 2 to 5 carbon atoms, carbamoyl or cyano andR.sub.2 is a group (a) to (i), groups (a) to (i) having the following significances: ##STR2## wherein n is 0 or 1 and R.sub.a, R.sub.b, R.sub.c and R.sub.d independently are hydrogen or alkyl of 1 to 4 carbon atoms; ##STR3## wherein R.sub.e is hydrogen or alkyl of 1 to 4 carbon atoms; ##STR4## wherein R.sub.h is halogen of atomic number of from 9 to 35; ##STR5## wherein R.sub.i together with R.sub.n is o-phenylene optionally substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or halogen of atomic number of from 9 to 35 and,when R.sub.3 is cyano,R.sub.i together with R.sub.n additionally is lower alkylene separating by 2 or 3 carbon atoms the nitrogen atom to which R.sub.i is bound from the nitrogen atom to which R.sub.n is bound andR.sub.

Abstract: This disclosure describes novel compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 each represent hydrogen, or ##STR2## and R.sub.3 is hydrogen or fluoro, andn is 1, 2 or 3, andprovided that one of R.sub.1 and R.sub.2 is other than hydrogen which are useful as anti-obesity agents.

Abstract: Fungicides are of the formula: ##STR1## wherein R and R' are each independently alkyl of 1 to 4 carbon atoms,R.degree. is trihalomethyl in which the halo atoms are of atomic weight of from 18 to 36, e.g. trifluoromethyl or trichloromethyl, cyano or --SO.sub.2 NR"R"', andR" and R"' are each independently hydrogen or alkyl of 1 to 4 carbon atoms.

Abstract: The present invention relates to compounds of formula I.sub.x, ##STR1## in which Y.sub.1 is (C.sub.1-6) alkoxy, Z is hydrogen, alkali metal or ammonium, andn is 1 or 2and a process for treating anionic dyeable substrates therewith to reserve the same against anionic dyes.

Abstract: Decahydro or octahydro-4-phenyl-cis-isoquinoline derivatives are useful as analgesics, anti-depressants, tranquilizers and sleep inducers.

Abstract: The invention relates to novel, polyoxyalkylene condensation products based on mixtures of primary, aliphatic alcohols, at least 70 mol % of which are branched 1-decanols, and to the use of these products as surface active agents.

Abstract: The present invention concerns compounds of formula ##STR1## wherein X is O, S or NH; n is 1 or 2 and A is a 5-membered heterocyclic ring, wherein the bicyclic system may be substituted.The compounds are useful as myotonolytic and anti-hypertensive agents.

Abstract: A non-irritating injectable dosage form of a tissue irritating medicament, comprising the medicament and a pharmaceutically acceptable glyceride vehicle comprising a glycerol ester of a saturated or unsaturated fatty acid having from 6 to 20 carbon atoms or mixtures thereof.

Abstract: The final products are compounds of the formula ##STR1## wherein (a) each of R.sup.1, R.sup.2 and R.sup.3 alkyl having from 1 to 22 carbon atoms; or(b) one or more is a phenyl or alkylphenyl type, n is from 3 to 20; andR is of an aralkyl-, phenyl-tryptophanyl- or benzocycloalkyl-type, eg D,L-5,5-dimethyl-5-sila-pentadecanoyl-1'-phenyl-2'-p-tolyl-ethylamide, are useful as antiatherosclerotic agents, and are prepared from corresponding carboxylic acids (or their derivatives).

Abstract: The present invention relates to quaternized polyamines having the basic structure of formula I, ##STR1## in which each R independently, is (C.sub.10-22)alkyl, (C.sub.10-22)alkenyl, phenyl(C.sub.1-3)alkyl or naphthyl(C.sub.1-3)alkyl,each R.sub.1, independently, is phenyl(C.sub.1-3)alkyl or naphthyl (C.sub.1-3)alkyl, z, is 1 to 5,each y.sub.1, independently is an integer from 2 to 8,y.sub.2, is an integer from 2 to 8, with the proviso that when z=1,y.sub.1 .noteq.y.sub.2 and when z>1 and the y.sub.1 's are the same y.sub.2 .noteq.y.sub.1and wherein an average of 0.5 to 2.0 nitrogen atoms are quaternized with alkyl radicals containing from 1 to 6 carbon atoms and mixtures of such quaternized polyamines with further quaternized polyamines, such polyamines and mixtures being useful as dye retarders/levelling agents.

Abstract: Anti-atherosclerotic agents of the formula: ##STR1## wherein R.sup.1 is (a) alkyl having from 1 to 22 carbon atoms; or(b) of the formula ##STR2## in which m is 0, 1 or 2, and each of R' and R" is, independently, hydrogen, halo or lower alkyl or alkoxy; R.sup.2 and R.sup.3 are joined to form with the silicon atom a heterocyclic ring having from 3 to 20 ring members; and R is an aralkyl-, phenyl- tryptophanyl- or benzocycloalkyl-type radical, eg 1-butyl-N-[(2-(4'-methyl-phenyl)-1-phenylethyl]-1-silacyclohexane propanamide, are obtained by reducing corresponding .alpha.,.beta.-unsaturated analogs.

Abstract: This invention provides new compounds of formula I, ##STR1## wherein R.sub.1, X, Y and Z are amino acid residues andeach B is hyrogen or together are a bond,useful as growth hormone secretion inhibitors.

Abstract: The present invention provides a pharmaceutical composition for controlled release of 4-(2-hydroxy-3-isopropylamino-propoxy) indole in the intestinal tract, admixed with sodium lauryl sulphate, and enteric coated.

Abstract: The present invention relates to cyclosporin derivatives, especially compounds of formula I ##STR1## wherein A is ##STR2## useful as anti-arthritic agents.

Abstract: Basic dyes free from sulfo groups of the formula ##STR1## in which Q signifies an unsubstituted or substituted phenyl or naphthyl radical,R.sub.1 and R.sub.2 signify hydrogen, unsubstituted or substituted alkyl, phenyl or cycloalkyl,R.sub.3 signifies hydrogen, unsubstituted or substituted alkyl or phenyl,the Z containing group signifies a heterocyclic diazo radical containing a quaternary ammonium group,R.sub.4 signifies unsubstituted or substituted alkyl, alkenyl, cycloalkyl or alkoxy,x signifies 1 to 3,A.crclbar. signifies an anion, andD signifies an unsubstituted or substituted phenylene or naphthylene radical are useful for dyeing and printing homo- and co-polymers of acrylonitrile and asymmetrical dicyanoethylene and synthetic polyamides and polyesters modified to contain acid groups. The obtained dyeings are level and fast to light and wet treatments.

Abstract: A finishing process for porous fibrous materials, especially for textiles, especially a dyeing process, in the presence of relatively small amounts of water and a foaming agent, is carried out at a liquor to material ratio of about 0.25:1 to 5:1. This water-saving finishing process leads to equal and level finishings especially important in the dyeing area.

Abstract: Method of treating sleep disturbance which comprises administering a compound of formula ##STR1## wherein R.sub.1 is phenethyl or butyrophenone optionally mono-substituted in the phenyl ring by fluorine, chlorine, bromine or lower alkyl or alkoxy, R.sub.2 is OR.sub.5 wherein R.sub.5 is lower alkyl or alkenyl or phenyl optionally mono-substituted by fluorine, chlorine, bromine, or alkoxy; or N(R.sub.6)R.sub.7 wherein R.sub.6 and R.sub.7 are each hydrogen, lower alkyl or cycloalkylalkyl, cycloalkyl, phenyl optionally mono-substituted by fluorine, chlorine, bromine, lower alkyl or lower alkoxy or lower phenylalkyl optionally mono-substituted in the phenyl ring by fluorine, chlorine, bromine or lower alkyl or alkoxy or R.sub.6 and R.sub.7 together with the nitrogen atom to which they are bound form a saturated heterocycle of 5 to 6 ring members, and either R.sub.3 is lower alkyl or cycloalkylalkyl, cycloalkyl or phenyl optionally mono-substituted by fluorine, chlorine, bromine or lower alkyl or alkoxy or, when R.

Abstract: Compounds of formula I ##STR1## selected from the group consisting of cyclosporin G, wherein A is ##STR2## dihydrocyclosporin G, wherein A is ##STR3## and isocyclosporin G, wherein A is ##STR4## are useful in treating inflammations and arthritis and as immuno-suppressant agents.